Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Home About Us Product Pipeline News Investors Contacts Careers

News

Recent Press Releases Archives

Recent Press Releases

2013 News Releases

Dec. 17, 2013 - Puma Biotechnology to Hold Conference Call to Provide Update on PB272 Clinical Trials in Patients with HER2 Mutations Read

Dec. 4, 2013 - Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL
Neratinib Graduates from I-SPY 2 TRIAL Read

Nov. 12, 2013 - Puma Biotechnology Reports Third Quarter 2013 Financial Results Read

Oct. 4, 2013 - Puma Biotechnology Initiates Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients Read

Sept. 4, 2013 - Puma Biotechnology to Present at Stifel Healthcare Conference Read

Aug. 6, 2013 - Puma Biotechnology Reports Second Quarter 2013 Financial Results Read

June 24, 2013 - Puma Biotechnology to Join Russell 3000 Index Read

June 7, 2013 - Puma Biotechnology Initiates Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Read

June 5, 2013 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference Read

May 29, 2013 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference Read

May 17, 2013 - Puma Biotechnology Comment on Trading Activity Read

May 14, 2013 - Puma Biotechnology to Present at UBS Global Healthcare Conference Read

May 9, 2013 - Puma Biotechnology Reports First Quarter 2013 Financial Results Read

May 8, 2013 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2013 Health Care Conference Read

April 1, 2013 - Puma Biotechnology Reports Fourth Quarter and Full Year 2012 Financial Results Read

Feb. 26, 2013 - Puma Biotechnology to Present at Cowen Health Care Conference Read

Feb. 20, 2013 - Puma Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Read

Feb. 6, 2013 - Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference Read


Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax